Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
deferred cytoreductive nephrectomy
ipilimumab
nivolumab
renal cell carcinoma
tertiary lymphoid structure
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
22
04
2021
revised:
08
06
2021
accepted:
25
06
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Tertiary lymphoid structure expression and immune checkpoint inhibitors have been attracting attention, and their relationship with renal cell carcinoma is controversial. Two patients with nivolumab plus ipilimumab treatment response for metastatic renal cell carcinoma underwent cytoreductive nephrectomy and regional lymph node dissection. In both cases, the renal tumor site expressed tertiary lymphoid structures. Despite the absence of treatment after a deferred cytoreductive nephrectomy and the short postoperative observation period, the patients still survived. Tertiary lymphoid structures were expressed in deferred cytoreductive nephrectomy specimen in cases treated with nivolumab plus ipilimumab.
Identifiants
pubmed: 34755054
doi: 10.1002/iju5.12347
pii: IJU512347
pmc: PMC8560443
doi:
Types de publication
Case Reports
Langues
eng
Pagination
355-358Informations de copyright
© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
ESMO Open. 2020 Nov;5(6):e001079
pubmed: 33246931
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Curr Opin Urol. 2021 May 1;31(3):262-269
pubmed: 33742979
Eur J Cancer. 2021 May;148:181-189
pubmed: 33743486
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33589528